A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Clinical Trial ID NCT02452424

PubWeight™ 12.37^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02452424

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Combination cancer immunotherapies tailored to the tumour microenvironment.	Nat Rev Clin Oncol	2015	1.54
2	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches.	Cancers (Basel)	2015	0.90
3	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.	Oncoimmunology	2016	0.84
4	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1.	J Gastrointest Oncol	2016	0.83
5	New advances in targeted gastric cancer treatment.	World J Gastroenterol	2016	0.81
6	Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.	Gynecol Oncol	2016	0.79
7	Emerging therapeutic targets in metastatic progression: A focus on breast cancer.	Pharmacol Ther	2016	0.79
8	Immunobiology and immunotherapy in genitourinary malignancies.	Ann Transl Med	2016	0.78
9	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.	Clin Cancer Res	2015	0.78
10	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond.	Ther Adv Med Oncol	2016	0.77
11	Future perspectives in cancer immunotherapy.	Ann Transl Med	2016	0.77
12	Prioritization schema for immunotherapy clinical trials in glioblastoma.	Oncoimmunology	2016	0.76
13	Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma.	Cancers (Basel)	2016	0.75
14	Current clinical immunotherapeutic approaches for head and neck cancer.	F1000Res	2016	0.75
15	Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.	Oral Oncol	2016	0.75